163 related articles for article (PubMed ID: 23111855)
21. A prospective study of pregravid oral contraceptive use and risk of hypertensive disorders of pregnancy.
Thadhani R; Stampfer MJ; Chasan-Taber L; Willett WC; Curhan GC
Contraception; 1999 Sep; 60(3):145-50. PubMed ID: 10640157
[TBL] [Abstract][Full Text] [Related]
22. Systemic Lupus Erythematosus and Pregnancy.
Lateef A; Petri M
Rheum Dis Clin North Am; 2017 May; 43(2):215-226. PubMed ID: 28390564
[TBL] [Abstract][Full Text] [Related]
23. Risk of tuberculosis comparison in new users of antitumour necrosis factor-α and with existing disease-modifying antirheumatic drug therapy.
Chan MJ; Wen YH; Huang YB; Chuang HY; Tain YL; Lily Wang YC; Hsu CN
J Clin Pharm Ther; 2018 Apr; 43(2):256-264. PubMed ID: 29119581
[TBL] [Abstract][Full Text] [Related]
24. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.
Lacaille D; Guh DP; Abrahamowicz M; Anis AH; Esdaile JM
Arthritis Rheum; 2008 Aug; 59(8):1074-81. PubMed ID: 18668604
[TBL] [Abstract][Full Text] [Related]
25. The impact of unrecognized autoimmune rheumatic diseases on the incidence of preeclampsia and fetal growth restriction: a longitudinal cohort study.
Spinillo A; Beneventi F; Locatelli E; Ramoni V; Caporali R; Alpini C; Albonico G; Cavagnoli C; Montecucco C
BMC Pregnancy Childbirth; 2016 Oct; 16(1):313. PubMed ID: 27756248
[TBL] [Abstract][Full Text] [Related]
26. Prepregnancy Endocrine, Autoimmune Disorders and the Risks of Gestational Hypertension-Preeclampsia in Primiparas: A Nationwide Population-Based Study in Taiwan.
Pan ML; Chen LR; Tsao HM; Chen KH
Int J Environ Res Public Health; 2020 May; 17(10):. PubMed ID: 32456015
[TBL] [Abstract][Full Text] [Related]
27. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
28. Medication Persistence of Disease-Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil.
Acurcio FA; Machado MA; Moura CS; Ferre F; Guerra AA; Andrade EI; Cherchiglia ML; Rahme E
Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1489-96. PubMed ID: 26814681
[TBL] [Abstract][Full Text] [Related]
29. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis.
Suissa S; Ernst P; Hudson M; Bitton A; Kezouh A
Am J Med; 2004 Jul; 117(2):87-92. PubMed ID: 15234643
[TBL] [Abstract][Full Text] [Related]
30. Perinatal use and discontinuation of disease-modifying anti-rheumatic drugs and biologics in women with rheumatoid arthritis: a cohort study.
Rebić N; Sayre EC; Zusman EZ; Amiri N; Baldwin C; De Vera MA
Rheumatology (Oxford); 2020 Jul; 59(7):1514-1521. PubMed ID: 31628479
[TBL] [Abstract][Full Text] [Related]
31. The effect of NSAIDs exposure on breast cancer risk in female patients with autoimmune diseases.
Hung CH; Lin YC; Chang YH; Lin YC; Huang HY; Yeh WJ; Wu TY; Hou MF
Eur J Cancer Prev; 2019 Sep; 28(5):428-434. PubMed ID: 30339576
[TBL] [Abstract][Full Text] [Related]
32. The risk of lymphoma development in autoimmune diseases: a meta-analysis.
Zintzaras E; Voulgarelis M; Moutsopoulos HM
Arch Intern Med; 2005 Nov; 165(20):2337-44. PubMed ID: 16287762
[TBL] [Abstract][Full Text] [Related]
33. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
34. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.
Kim MY; Buyon JP; Guerra MM; Rana S; Zhang D; Laskin CA; Petri M; Lockshin MD; Sammaritano LR; Branch DW; Porter TF; Merrill JT; Stephenson MD; Gao Q; Karumanchi SA; Salmon JE
Am J Obstet Gynecol; 2016 Jan; 214(1):108.e1-108.e14. PubMed ID: 26432463
[TBL] [Abstract][Full Text] [Related]
35. Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study.
Etminan M; Carleton BC; Samii A
J Clin Neurosci; 2008 May; 15(5):576-7. PubMed ID: 18343119
[TBL] [Abstract][Full Text] [Related]
36. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR
Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901
[TBL] [Abstract][Full Text] [Related]
37. Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study.
Tsao NW; Sayre EC; Hanley G; Sadatsafavi M; Lynd LD; Marra CA; De Vera MA
Ann Rheum Dis; 2018 Jun; 77(6):869-874. PubMed ID: 29496718
[TBL] [Abstract][Full Text] [Related]
38. Systemic lupus erythematosus pregnancies: the Sarawak experience and review of lupus pregnancies in Asia.
Teh CL; Wong JS; Ngeh NK; Loh WL
Rheumatol Int; 2011 Sep; 31(9):1153-7. PubMed ID: 20349069
[TBL] [Abstract][Full Text] [Related]
39. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
Kim SC; Solomon DH; Liu J; Franklin JM; Glynn RJ; Schneeweiss S
Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
[TBL] [Abstract][Full Text] [Related]
40. Prediction of Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus.
Palma Dos Reis CR; Cardoso G; Carvalho C; Nogueira I; Borges A; Serrano F
Clin Rev Allergy Immunol; 2020 Dec; 59(3):287-294. PubMed ID: 31444781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
